Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up – Should You Buy?

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) gapped up before the market opened on Tuesday . The stock had previously closed at $37.00, but opened at $39.8701. Swedish Orphan Biovitrum shares last traded at $39.8701, with a volume of 100 shares changing hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BIOVF shares. BNP Paribas Exane upgraded Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Danske lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. Finally, Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The company has a debt-to-equity ratio of 0.14, a current ratio of 0.90 and a quick ratio of 0.59. The company has a fifty day moving average price of $38.76 and a 200 day moving average price of $35.70. The company has a market capitalization of $14.19 billion, a P/E ratio of 306.72 and a beta of 0.35.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Swedish Orphan Biovitrum had a return on equity of 15.74% and a net margin of 1.43%.The business had revenue of $846.23 million for the quarter, compared to the consensus estimate of $879.40 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.